Winning the Drug Development Debate
We create two new companies around academic inventions every day of the year. The critical role such companies play in drug development is clear. The successful integration of public research...
View ArticleMake American Innovation Great Again
It's a fundamental principal of economics that the secure ownership of personal property is essential for prosperity. Walk through any public park and see how seldomly people bother to pick up trash...
View ArticleCommercialization of University Research Threatened by Proposed State...
EFF’s Reclaim Invention Act, Draft Model Statute may seem an odd approach to folks in DC but when lined up with a state-level lobby of IP-uninformed and angry local businesses lobby, state legislators...
View ArticleAdvice for the Trump Administration and New Congress: Protect Bayh-Dole and...
Bayh-Dole is running on autopilot without Executive branch oversight and U.S. patents are no longer the world's gold standard. Without a course correction, we could be headed back to the bad old...
View ArticleThe National Cancer Institute Didn’t Deserve This Treatment From the New York...
While those in the military are often thanked for their service, let's also thank researchers like Dr. Rosenberg and his colleagues who spend their lives trying to alleviate human suffering. But that...
View ArticleEarly Stage Innovation’s Chance to Save Itself
Universities in particular must explain to their congressional delegations why R&D must continue to be funded and why its Bayh-Dole based commercialization bridge must be protected so federal funds...
View ArticleThe Plight of the Public Sector Entrepreneur
Being an entrepreneur isn't easy. While it is a tough road for anyone, it's particularly tough if you're in the public sector and threatened by politicians... Rather, the march in provision is intended...
View ArticleAcademic Patent Licensing Helps Drive the U.S. Economy
What's even more impressive is the impacts on gross industry output and GDP are up 14% while the number of U.S. jobs supported rose 12% since the previous report issued two years ago. That's...
View ArticleBernie Sanders’ Really Bad Idea
Sen. Bernie Sanders (I-VT) introduced legislation requiring every agency and non-profit entity to include a "reasonable pricing" provision based on King's formula for any life science invention made...
View ArticleConservatives’ Letter to U.S. Senate Says Preserve Bayh-Dole
Though aimed at certain pharmaceutical products, Sens. Angus King’s and Bernie Sanders’ potential amendments would throw the key to the Bayh-Dole Act’s success —certainty and exclusivity of the...
View ArticleThink Twice Before Pulling the Plug on Tech Transfer
Most assaults on public/private sector R&D partnerships are launched by those who believe patents are inherently bad and that through some undefined magic publicly funded inventions will be...
View ArticleThe changing face of university technology transfer
Today (TTOs) are increasingly being run by professionals who are experienced in startups, licensing, monetizing and have tremendous depth of technical knowledge in a variety of fields. But they are all...
View ArticleWhen Big Brother Comes Marching In: Patent Challenges on Entrepreneurial...
Bayh-Dole has recently come under attack, as some are trying to highjack certain provisions to be used as a cost control measure for novel therapeutics as the cost of drugs skyrocket. Should the...
View ArticleFine Tuning the Trump Administration’s ROI Initiative
The Trump Administration's Return on Investment (ROI) Initiative, which is geared toward increasing the American taxpayer's benefits from federally-supported R&D, is potentially a big step forward....
View ArticleHappy Birthday, Senator Birch Bayh
Hopefully, you've been fortunate enough—at least once in your life—to work for someone you really admired. That happened to me as a Senate Judiciary Committee staffer for Senator Birch Bayh (D-IN), who...
View Article
